CTRI/2016/07/007096尚未招募1 期
An assesor blind, balanced, randomized, two-treatment, two period, single-dose, two way crossover, comparative subcutaneous pharmacokinetic and pharmacodynamic study of two dose levels of INTP5 of Intas pharmaceuticals ltd., India Ahmedabad, India with two dose levels of Neulasta of Amgen (EU licensed product) in healthy, normal adult human subjects under fasting condition. - NA
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 344
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Non-smoking, healthy, normal, adult human volunteers between 18 to 45 years of age (both inclusive) living in and around Ahmedabad city or western part of India.
- •2. Having a Body Mass Index (BMI) between 18.5 â?? 24.9 kg/m2 (both inclusive), and weight not <50 kg or > 100 kg.
- •3. Not having any significant disease in medical history or clinically significant abnormal findings during screening, abdominal ultrasonography, medical history, physical examination, laboratory evaluations, 12-lead ECG and X-ray chest (P/A view) recordings.
- •4. Ability to communicate effectively with study personnel.
- •5.Willingness to adhere to the protocol requirements.
- •6. Able to understand and give written informed consent for participation in the trial.
- •7. Both male and female patients of child bearing potential must be practicing adequate contraception.Female patients of child-bearing potential must not be orlikely to be pregnant or lactating and must have a negative serum pregnancy test at screening and negative urine pregnancy test at randomization.
排除标准
- •1. Known hypersensitivity to the study drug or its constituents
- •2. Known case of hereditary fructose intolerance
- •3. Any clinically significant laboratory finding including ANC (Absolute Neutrophil Count), CD 34+, platelet or hemoglobin at the time of screening.
- •4. History or presence of other systemic disorders or diseases (e.g., haemopoietic, renal, hepatic, cardiovascular, respiratory, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement).
- •5. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.
- •6. Subjects with a history of pulmonary infiltrate or pneumonia in the previous 6 months from the date of the screening visit.
- •7. History of any hematologic disease including sickle cell disorders
- •8. Receipt of over-the-counter medicines which have not yet cleared from the body (five half-lives must have passed for the medicine to be considered to have cleared from the body).
- •9. Smokers, or who have smoked within last six months prior to start of the study.
- •10. Consumption of tobacco or tobacco containing products within last six months prior to start of the study.
- •11. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
- •12. The presence of clinically significant abnormal laboratory values during screening.
- •13. Positive result for human immunodeficiency virus (HIV I &/or II) and/or hepatitis B and C tests.
- •14. History or presence of psychiatric disorders.
- •15. Consumption of grape fruit or grape fruit products within 72 hours prior to receiving study drug.
- •16. A history of difficulty in donating blood.
研究者
相似试验
尚未招募
不适用
A Study of Injections of Pegfilgrastim in Healthy, Adult Human Subjects.CTRI/2018/02/011700Intas Pharmaceuticals Ltd
已完成
不适用
PHARMACOKINETIC, PHARMACODYNAMIC BIOEQUIVALENCE STUDY ON VB70G(INSULIN GLARGINE INJECTION) 100 IU/ML - FASTINGCTRI/2022/08/044806Virchow Biotech Private Limited40
尚未招募
1 期
Comparative bioavailability/ bioequivalence study of Lutein formulations - Product C and Product D (Lutein 20 mg/capsule) supplementation in healthy, adult humans, after receiving high-fat, high-calorie breakfast.CTRI/2018/08/015403Mr Abhijeet Morde
尚未招募
1 期
To Compare the bioavailability of Lutein formulations - Product A and Product B (Lutein 10 mg/Zeaxanthin 2 mg per capsule) supplementation in healthy, adult human subjects under fed conditions.CTRI/2019/11/022082Mr Abhijeet Morde
尚未招募
1 期
Comparative bioavailability/ bioequivalence study of Lutein formulations - Product A and Product B (Lutein 20 mg/capsule) supplementation in healthy, adult humans, after receiving high-fat, high-calorie breakfast.CTRI/2018/08/015507Mr Abhijeet Morde